Precision Oncology
Decision Support

Quantifying Chemotherapy resistance for Informed Clinical Action

“Our platform doesn't tell doctors what to do. It delivers a data driven second opinion quantifying the probability of success or failure so clinicians can confidently decide whether to continue, adjust or monitor treatment.”

70% Resistance

12% Survival

The Global Challenge &
Regional Impact

Across 2.3 million annual global cases, drug resistance remains the primary cause of treatment failure. Ineffective therapy adds up to $5,320/month in toxicity management costs. Rising incidence in younger populations requires precise first line selection to preserve long term productivity and family stability.

Our impact in Africa, high mortality with a 33%, 7 year survival in Sub-saharan regions. 77% of patients face catastrophic health expenditure due to “trial and error” costs.

Our Research Publications

INVESTIGATING CHEMOTHERAPY RESISTANCE
IN BREAST CANCER

Dr. Shamim Nabuuma Kaliisa, MRes Data Science for Health

As a researcher, I have examined numerous medical publications to understand the systematic failure of breast cancer to respond to therapeutic interventions. My background in a Master of Research in patient datasets⁵. My findings indicate that chemotherapy resistance is far from a singular mechanical failure, rather it is a sophisticated, multi-layered defensive strategy orchestrated by the malignancy itself^5,6.

Core Platform Values

Quantified Probability: Replaces binary predictions with statistical confidence scores allowing oncologists to move beyond “gut feelings” to data backed decisions.

Clinical Co-pilot: Enhances physician autonomy by providing the evidence needed for hospital tumor boards and insurance authorizations.

Toxicity Avoidance: Identifies high resistance risks early, sparing patients from the physical toll of ineffective, highly toxic regimens.

Treatment Agnostic: Evaluates standard and emerging protocols without bias, ensuring the patient's first choice is their best choice.

Precision Oncology Decision Support